Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Sep;1(1):2-3.
doi: 10.1016/S2468-1253(16)30016-4. Epub 2016 Jun 21.

Infliximab or ciclosporin for acute severe ulcerative colitis?

Ashwin N Ananthakrishnan  1
Affiliations
Comment

Infliximab or ciclosporin for acute severe ulcerative colitis?

Ashwin N Ananthakrishnan. Lancet Gastroenterol Hepatol. 2016 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Financial conflicts of interest: None

Comment on

References

    1. Kaplan GG, Seow CH, Ghosh S, et al. Decreasing colectomy rates for ulcerative colitis: a population-based time trend study. Am J Gastroenterol. 2012;107:1879–87. - PubMed
    1. Ananthakrishnan AN, McGinley EL, Binion DG, et al. A nationwide analysis of changes in severity and outcomes of inflammatory bowel disease hospitalizations. J Gastrointest Surg. 2011;15:267–76. - PubMed
    1. Narula N, Marshall JK, Colombel JF, et al. Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids. Am J Gastroenterol. 2016;111:477–91. - PubMed
    1. Seah D, De Cruz P. Review article: the practical management of acute severe ulcerative colitis. Aliment Pharmacol Ther. 2016;43:482–513. - PubMed
    1. Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet. 2012;380:1909–15. - PubMed

LinkOut - more resources